Table 2

High platelet activation and EV levels are found in patients with SLE at baseline

HealthySLEPvalue
(n=30)(n=98)
ATX, ng/mL257.8 (219.9; 340.1)251.4 (199.1; 333.9)0.2442
Platelet, %(n=30)(n=40)
PAC1+3.65 (1.10; 8.50)7.85 (2.88; 15.75)0.0140
PAC1+ ATX+0.60 (0.20; 1.00)1.90 (0.60; 4.30)0.0042
CD62P+2.35 (1.70; 4.30)5.55 (2.33; 9.53)0.0059
CD62P+ ATX+0.70 (0.30; 0.80)1.35 (0.60; 4.35)0.0046
PAC1+ CD62P+0.70 (0.40; 1.40)2.00 (0.90; 4.98)0.0006
PAC1+ CD62P+ ATX+0.28 (0.15; 0.63)0.85 (0.379; 3,24)0.0020
EVs, EVs/µL(n=30)(n=102)
PEVs479 (275; 1074)3569 (1752; 7144)<0.0001
PS+ PEVs377 (221; 816)3228 (1601; 6260)<0.0001
REVs424 (296; 603)1936 (851; 4495)<0.0001
PS+ REVs91 (55; 144)1064 (171; 2294)<0.0001
  • Results are presented as median (IQR), pvalue based on Wilcoxon Mann Whitney test. Significant pvalues are in bold.

  • ATX, autotaxin; EV, extracellular vesicle; IQR, interquartile range; PEV, platelet EV; PS+, phosphatidylserine positive; REV, red blood cell EV ; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.